Nuveen’s Aktis Oncology AKTS Stock Holding History

Nuveen’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	49,816 +25,348	+104%	+$521K	﹤0.01%	2693
2026 Q1	$438K	Buy	+24,468	New	+$475K	﹤0.01%	2894

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Nuveen's AKTS Position: Q2 2026 in Review

Nuveen increased its Aktis Oncology (AKTS) stake by 104% in Q2 2026, buying an estimated $521K and bringing the position to 49,816 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2693.

Nuveen first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Nuveen held 49,816 shares of Aktis Oncology worth $1.61M as of Q2 2026.
Nuveen bought 25,348 Aktis Oncology shares in Q2 2026, an estimated $521K.
Aktis Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2693 holding.
Nuveen first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.